How we can work together
We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.
Search results
We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.
Opus Genetics, a clinical-stage biopharmaceutical company, has recently announced that the U.S Food and Drug Administration has cleared its Investigational New Drug application for OPGx-RDH12. OPGx-RDH12 is an investigational gene therapy in development for the treatment of RDH12-associated Leber Congenital Amaurosis (LCA).
Atsena Therapeutics, a clinical-stage gene therapy company, has completed an important but early milestone by selecting the version of ATSN-401 that they will develop as a potential treatment for Stargardt disease, known as the lead clinical candidate.
KIO-301, an experimental ‘photoswitch’ drug in development by Kiora Pharmaceuticals has shown encouraging safety results in early-stage testing and is now being evaluated in a phase 2 study known as ABACUS-2. It is currently being trialled in those with advanced RP, with the potential to expand into choroideremia and stargardt disease.
VeonGen has reported encouraging early results from a clinical trial of VG801, an investigational gene therapy for Startgardt disease, a genetic retinal condition that currently has no approved treatments.
Researchers in the Netherlands are developing a “retina-on-a-chip” that mimics the key layers of the human retina, offering a powerful new way to study inherited retinal diseases (IRDs) and test potential treatments using human cells.
The latest research news piece from Retina UK.
The latest research news from Retina UK.
The Spring 2023 edition of the Retina UK newsletter, Look Forward, which includes articles about our upcoming events, research updates and more.
Hajrah Sarkar is a PhD student whose project is funded by Retina UK.